angiotensin-converting enzyme inhibitor


Also found in: Dictionary, Thesaurus, Medical.

angiotensin-converting enzyme inhibitor:

see ACE inhibitorACE inhibitor
or angiotensin-converting enzyme inhibitor
, drug used to reduce elevated blood pressure (see hypertension), to treat congestive heart failure, and to alleviate strain on hearts damaged as a result of a heart attack (see infarction).
..... Click the link for more information.
.
Mentioned in ?
References in periodicals archive ?
Fiskio et al., "An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors," Journal of Evaluation in Clinical Practice, vol.
Patients in the placebo group were unable to receive an angiotensin-converting enzyme inhibitor during the study.
Acute hypotensive transfusion reaction with concomitant use of angiotensin-converting enzyme inhibitors: a case report and review of the literature.
Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca: isolation, elucidation of structure and synthesis.
Coreg is an excellent drug for this problem, and often an angiotensin-converting enzyme inhibitor or receptor blocker is added.
The two trials will compare standard therapy using an angiotensin-converting enzyme inhibitor (ACE-inhibitor) to intensive therapy using both an ACE-inhibitor and an angiotensin receptor blocker (ARB).
The UP-induced activation of ERK1/2 and p38 was attenuated by captopril, an angiotensin-converting enzyme inhibitor. These results indicate that activation of the local renin-angiotensin system may play an important role in cardiovascular effects induced by PM.
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
* 62.2% of residents with congestive heart failure were not receiving an angiotensin-converting enzyme inhibitor.
Fosinopril, an angiotensin-converting enzyme inhibitor marketed as Monopril by Bristol-Myers Squibb, was granted "pediatric exclusivity" in January 2003, Under The Best Pharmaceuticals for Children Act, exclusivity is granted to companies who perform pediatric studies of their products in exchange for a 6-month extension on the drug's patent.
Juan Leon, from the same laboratory (NWU), showed that captopril, an antifibrotic angiotensin-converting enzyme inhibitor, is effective in ameliorating experimental autoimmune myocarditis and experimental Chagas heart disease.

Full browser ?